Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
18.72
-0.15 (-0.79%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Amphastar Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Amphastar Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of $22. The average 1-year stock price forecast is 17.52% higher than the current stock price, while the lowest is $19 (+1.50%) and the highest is $30 (+60.26%).
Price Target: $22 (+17.52%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Amphastar Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 4 | 4 | 5 | 7 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Hold Maintains $30 | Hold | Maintains | $30 | +60.26% | Jul 23, 2026 |
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jul 8, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Downgrades $25 → $20 | Sell | Downgrades | $25 → $20 | +6.84% | Jun 29, 2026 |
| Barclays | Barclays | Hold Reiterates $23 → $20 | Hold | Reiterates | $23 → $20 | +6.84% | Jun 3, 2026 |
| Wells Fargo | Wells Fargo | Hold Downgrades $30 → $19 | Hold | Downgrades | $30 → $19 | +1.50% | May 14, 2026 |
Financial Forecast
Revenue This Year
745.19M
from 719.89M
Increased by 3.52%
Revenue Next Year
778.70M
from 745.19M
Increased by 4.50%
EPS This Year
2.56
from 3.25
Decreased by -21.33%
EPS Next Year
2.96
from 2.56
Increased by 15.76%
EPS and Forward PE are based on non-GAAP adjusted numbers.